HackensackUMC Mountainside Offers New Treatment for Prostate Cancer

September 13, 2013 05:08 AM

Read this story as seen in the Montclair Times.
HackensackUMC Mountainside announces the availability of Xofigo® (radium Ra 223 dichloride) in their treatment of certain men with advanced prostate cancer. The drug, which was approved by the Food and Drug Administration (FDA) earlier this year, is intended for use in men whose cancer has spread (metastasized) to their bones, who have symptoms from their cancer and who have already received treatment to lower testosterone levels. This new treatment, given intravenously, delivers radiation directly to cancer cells in the patient’s bones while minimizing damage to surrounding normal tissue. Ra-223 emits alpha particles that are less toxic to bone marrow than older radiopharmaceuticals that relied on beta particles.

"This is a fantastic addition to our treatment armamentarium of advanced-stage prostate cancer and we are pleased to be the first hospital in the state licensed to administer Xofigo®,” states Dr. John Conti, Co-Director of the Cancer Center. “Xofigo® specifically targets cancer cells in the bone and has some advantages over other types of radiation therapy. A full course of treatment consists of six quick injections given at four-week intervals, while traditional external radiation to bone may involve daily treatments over several weeks. It is not only a safer option, but also has the potential to prolong the lives of men with this form of prostate cancer. What’s more, unlike other drugs of its kind, there are no limitations on physical contact nor proximity after treatment,” he adds.

According to the American Cancer Society, prostate cancer remains the most common cancer among men, after skin cancer. About one in six men will develop the illness during his lifetime, but it can often be treated successfully. Caught early, it is often curable, and more than 2 million men in the United States count themselves as prostate survivors.

To find out if you are a candidate for treatment with Xofigo®, please consult your oncologist. For a referral to an oncologist at HackensackUMC Mountainside please call (888) 973-4MSH.

At HackensackUMC Mountainside, patients have immediate access to innovative and effective treatment alternatives at specialized centers within the hospital that focus on imaging, women’s health, cancer care, surgery, obesity, stroke and chronic kidney disease. The 365-bed community hospital also serves as a learning center via its nursing school and residency programs. HackensackUMC Mountainside is designated as a Primary Stroke Center by the NJ State Department of Health and Senior Services and is one of only a few community hospitals licensed by the State to perform emergency angioplasty. To learn more about HackensackUMC Mountainside visit www.mountainsidehosp.com.



close (X)